This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
This pharmaphorum webinar, held in association with Savana, will take place on Thursday 22 April from 16:00-17:00 BST / 17:00-18:00 CET / 10:00-11:00 EST and hear from presenters at BREATHE – the health dataresearch hub for respiratory health, Salford Royal NHS Foundation Trust and Savana.
The webinar explored the potential of the technology to process the vast amount of data languishing untapped in EHRs, while ensuring that patient data privacy and safety is maintained at all times. Ignacio is in demand as an international speaker at digital health, clinicalresearch, science and technology events and congresses.
If you hadn’t already noticed, the clinicalresearch enterprise has well and truly entered the era of “bigdata,” artificial intelligence (AI), and machine learning. It also includes search and support services that help patients understand, find, and enroll in clinical trials.”
The Indian life sciences sector is making strides by integrating quantum computing, artificial intelligence (AI), machine learning (ML), advanced analytics, bigdata, internet of things (IoT) and blockchain into their research and development efforts.
Countries like Estonia and Finland have taken on a completely digitised approach to their health services , integrating EHR data to efficiently prescribe medications and improve treatment strategies. Darwin EU is part of the EMA BigData Steering group that aims to increase the utility of BigData in regulatory decision-making.
Landry is a professor of medicine and epidemiology at Oxford Population Health and deputy director of the University of Oxford’s BigData Institute. ElZarrad is the director of the Office of Medical Policy in the FDA’s Center for Drug Evaluation and Research.
Just in time to help recognize Pride Month , ACRP’s ClinicalResearcher journal is pleased to share the first details from the lead peer-reviewed article on “Improving Cardiovascular Research for Transgender and Gender Diverse Populations” from a trio of WCG IRB expert contributors to the new issue going online today (June 13).
With more healthcare facilities transitioning from paper charts to electronic records and electronic health records (EHRs) becoming more integrated and technologically advanced, EHRs are expected to drive big changes in the provision of healthcare and clinicalresearch delivery.
Some of the medical advances with the technology are genomics and epigenetics, BigData, AI and ML which are allowing molecular […] Technology adoptions like artificial intelligence and machine learning are bringing in major transformation in the way a primary physician will extend treatment protocols.
Just in time to help recognize Pride Month , ACRP’s ClinicalResearcher journal is pleased to share the first details from the lead peer-reviewed article on “Improving Cardiovascular Research for Transgender and Gender Diverse Populations” from a trio of WCG IRB expert contributors to the new issue going online today (June 13).
Just in time to help recognize Pride Month , ACRP’s ClinicalResearcher journal is pleased to share the first details from the lead peer-reviewed article on “Improving Cardiovascular Research for Transgender and Gender Diverse Populations” from a trio of WCG IRB expert contributors to the new issue going online today (June 13).
Real-world evidence (RWE) is emerging as an important area of research to reveal, in real time, new insights and innovations and is accelerating the development of new and innovative therapies and treatments to improve patient outcomes.
Pérez-Stable, MD, Director of the National Institute on Minority Health and Health Disparities (NIMHD), shared his thoughts on national priorities for reducing health disparities and opportunities for clinicalresearchers to help promote health equity.
We know that the demand at the site level for studies is growing and the workforce capacity is shrinking, notes Bree Burks, RN, MSN, Vice President of Strategy for Veeva Systems, who will present on The ClinicalResearch Technology Reboot: Are We Getting it Right? The ClinicalResearch Technology Reboot: Are We Getting it Right?
Attendees will learn more about how an SCA was used at the design and execution phases in a recent study of new treatments for relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) and will also receive an eBook ‘How to harness the potential of AI and real-world data for clinicalresearch’. About the panel.
Through these collaborations, advanced technologies tied to AI and bigdata are being employed to develop personalized and targeted medicines, ultimately leading to more effective treatments for diseases like cancer and immune deficiencies,” Lyons notes.
With this, we can elevate and simplify the clinical trial experience for research professionals and participants. More accurate data. Data collected via mobile app is arguably cleaner and more objective than traditional methods in clinicalresearch. Power behind BigData.
The big headline out of the health care M&A world today is Swiss pharmaceutical giant Roche’s $1.9 billion acquisition of Flatiron Health, the Alphabet-backed, cancer-focused digital health analytics upstart that’s attempting to use real world patient information and bigdata to spur better oncology R&D.
The big headline out of the health care M&A world today is Swiss pharmaceutical giant Roche’s $1.9 billion acquisition of Flatiron Health, the Alphabet-backed, cancer-focused digital health analytics upstart that’s attempting to use real world patient information and bigdata to spur better oncology R&D.
It was a time when “the potential for systematic understanding of complex biology was palpable”, a fascinating terrain wherein the “first bacterial genomes were being sequenced”, when microarray technology was in the early stages of being invented, and ‘genomics’ and ‘bigdata’ certainly weren’t on the tips of people’s tongues.
The Wall Street Journal has an interesting article on the use of “BigData” to identify and solicit potential clinical trial participants. The premise is that large consumer data aggregators like Experian can target patients with certain diseases through correlations with non-health behavior.
Companies wishing to take part in the pilot can contact the EMA here, and those selected will be able to file their applications, including raw data from September of this year.
We are all aware that the process between patient identification and enrollment is significantly inefficient and ineffective, especially for those patients that are currently not getting treatment in research-oriented sites.
Clinical trials for different kinds of drugs often mandate differences in the patient pools. Technologies such as bigdata and deep learning enable algorithms to understand and correlate patient-specific genetic markers to better assess potential participants.
Rise of the machines – bigdata, AI and machine learning. Companies will capitalise on tech advances in the areas of data use to inform R&D and/or provide personalised care to patients. Patients are beginning to expect the providers of their medicines to help them with their condition and the impact on their lives.
In order to gain marketing approval from regulatory authorities for a novel therapeutic intervention, highly accurate and elaborate clinical trial data is required to validate the drug’s safety and effectiveness towards a specific target indication. Researchers collect data from people and compare changes throughout time.
As we explore Genmab’s strategic vision, technological advancements and the next frontier in antibody research, we gain insights into the future of medicine — a future where Genmab’s cutting-edge therapies are poised to transform patient care and meet the complex challenges of the next generation of healthcare.
“We need networks of healthcare providers that can share that data, but we also need methods and tools to recruit patients for that research.”. Her research area is the secondary use of observational data of patients with rare and unclear diseases; with attention to the researchdata infrastructure and terminologies.
Although approach differs slightly amongst organizations in clinicalresearch, everyone agrees on this: it’s time for the industry to become more agile. Too many life-saving treatments and medical advancements are at stake to remain attached to the traditional ways of data collection.
International deep real-world evidence company Savana is on a mission to give health researchers the power to unlock the clinical value embedded within electronic health records (EHRs) using artificial intelligence (AI) and clinical Natural Language Processing (NLP) techniques.
This is a relatively new model of clinical trials in terms of adoption and is, therefore, the highly underutilized method of conducting clinicalresearch. This prompt data entry facility reduces any chance of data loss or the need to remember every minuscule information by patients.
Syntegra has also engaged with the Federal Drug Administration (FDA) to evaluate the role of synthetic data in regulatory decisions, for COVID-19 and beyond.
With the COVID-19 pandemic, there has never been a time when rapid, low burden access to patient-level data, at scale, was more urgent” says Michael D.
The clinical trials landscape is evolving more rapidly than ever before. Meanwhile, decentralisation and the BigData revolution are transforming the way researchers run clinical trials, and previously untapped geographies are emerging as new hubs for future research. of the global trial landscape.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content